Clinical Trials
7 trialsNCT03295396 2025-07-28
ONC201 in Adults With Recurrent H3 K27M-mutant Glioma
Jazz Pharmaceuticals
Phase 2 Terminated
NCT02525692 2024-12-24
Oral ONC201 in Adult Recurrent Glioblastoma
Jazz Pharmaceuticals
Phase 2 Terminated
NCT03485729 2024-12-24
ONC201 in Recurrent or Metastatic Type II Endometrial Cancer Endometrial Cancer
Jazz Pharmaceuticals
Phase 2 Terminated
NCT02863991 2024-07-03
Oral ONC201 in Relapsed/Refractory Multiple Myeloma
Jazz Pharmaceuticals
Phase 1/2 Terminated
NCT03791398 2023-02-17
379
Brown University
Phase 1/2 Terminated
NCT02420795 2022-04-04
Akt/ERK Inhibitor ONC201 in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma
M.D. Anderson Cancer Center
Phase 1/2 Terminated
NCT03733119 2022-03-10
ONC201 With a Methionine-Restricted Diet in Patients With Metastatic Triple Negative Breast Cancer
University of Wisconsin, Madison
Phase 2 Terminated